• Earlier this week, Amphastar Pharmaceuticals director Floyd Petersen exercised 16,679 stock options and sold the resulting shares for about US$441,800, shortly after the company secured FDA approval for its teriparatide injection prefilled pen for severe osteoporosis.
• This FDA green light not only broadens Amphastar’s treatment portfolio in a high‑need bone health market, but also arrives alongside an ongoing multi‑year share repurchase program that has already retired over 14.10 million shares since 2016.
• We’ll now explore how FDA approval of the teriparatide prefilled pen could reshape Amphastar’s investment narrative and future growth profile.

These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

Amphastar Pharmaceuticals Investment Narrative Recap

To own Amphastar, you need to believe it can turn its injectable and intranasal platform, expanding U.S. manufacturing base, and growing branded portfolio into steady, profitable growth despite recent earnings pressure. The FDA approval of its teriparatide prefilled pen looks like a helpful but not transformational near term catalyst, while the biggest immediate risk remains that recent profit margin compression and earnings declines continue to weigh on sentiment if new launches do not offset that trend.

The company’s ongoing multi year share repurchase program, which has already retired more than 14.10 million shares since 2016 and was increased by US$50 million in August 2025, is the clearest context for this insider option exercise and sale. For investors, buybacks paired with new product approvals can support the long term narrative, but they do not eliminate the earnings and margin risks that have shown up in the latest quarterly results.

But investors should also be aware that...

Amphastar Pharmaceuticals' narrative projects $830.2 million revenue and $142.5 million earnings by 2028.

Uncover how Amphastar Pharmaceuticals' forecasts yield a $32.00 fair value, a 19% upside to its current price.

Exploring Other Perspectives

Three fair value estimates from the Simply Wall St Community span roughly US$32 to about US$97 per share, showing how far apart individual views can be. Against that backdrop, Amphastar’s recent earnings decline and margin compression give you an important counterpoint to consider as you weigh these different perspectives.

Explore 3 other fair value estimates on Amphastar Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Build Your Own Amphastar Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Amphastar Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Amphastar Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amphastar Pharmaceuticals' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• Find companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.